Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
106
datasets available to search
ShareScore release 0.9.0
Dataset results
106 results for “BRAF inhibitors”
microRNA profiles of melanoma samples from patients responsive or resistant to BRAF inhibitor
GEO Series GSE312671. Homo sapiens. 90 samples. Type: Non-coding RNA profiling by array.
Withdrawal of MEK1/2 inhibitor reverses acquired resistance driven by BRAF amplification but drives EMT and chemoresistance in cells with amplified KRAS
GEO Series GSE120993. Homo sapiens. 36 samples. Type: Expression profiling by array.
Loss of tumor cell MHC Class II drives MAPK-inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers [RNA-seq]
GEO Series GSE302629. Mus musculus. 24 samples. Type: Expression profiling by high throughput sequencing.
BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells – insights into mode of action and resistance mechanisms
GEO Series GSE245262. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Gene and microRNA expression profiling of a melanoma cell line resistant to BRAF inhibitor PLX4032 compared to the parental sensitive counterpart
GEO Series GSE68841. Homo sapiens. 15 samples. Type: Expression profiling by array; Non-coding RNA profiling by array.
Wnt5A Enhances Resistance of Melanoma Cells to Targeted BRAF Inhibitors
GEO Series GSE55583. Homo sapiens. 10 samples. Type: Expression profiling by array.
RNA-seq data of BRAF wild-type and BRAF mutant tumor cells treated with the ERK inhibitor GDC-0994
GEO Series GSE264049. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Gene and microRNA expression profiling of a melanoma cell line resistant to BRAF inhibitor PLX4032 compared to the parental sensitive counterpart (mRNA)
GEO Series GSE68840. Homo sapiens. 7 samples. Type: Expression profiling by array.
Suppression of heparan sulfation resensitizes YAP1-driven BRAF mutant melanoma to MAPK pathway inhibitors
GEO Series GSE193775. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing.
New compounds triggering endoplasmic reticulum stress exert anti-melanoma effects and overcome BRAF inhibitor resistance
GEO Series GSE79071. Homo sapiens. 6 samples. Type: Expression profiling by array.
SAKE (Single-cell RNA-Seq Analysis and Klustering Evaluation) Identifies Markers of Resistance to Targeted BRAF Inhibitors in Melanoma Cell Populations
GEO Series GSE108397. Homo sapiens. 337 samples. Type: Expression profiling by high throughput sequencing.
Effect of combination treatment with BRAF and MEK inhibitors (BRAFi/MEKi) in BRAFV600E mutant cell lines using RNAseq
GEO Series GSE186108. Homo sapiens. 10 samples. Type: Expression profiling by high throughput sequencing.
BRAF inhibitors enhance erythropoiesis and treat anemia through paradoxical activation of MAPK signaling
GEO Series GSE221242. Homo sapiens. 4 samples. Type: Expression profiling by high throughput sequencing.
SAKE (Single-cell RNA-Seq Analysis and Klustering Evaluation) Identifies Markers of Resistance to Targeted BRAF Inhibitors in Melanoma Cell Populations [Bulk RNA-Seq]
GEO Series GSE108382. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing.
SAKE (Single-cell RNA-Seq Analysis and Klustering Evaluation) Identifies Markers of Resistance to Targeted BRAF Inhibitors in Melanoma Cell Populations [Fluidiam scRNA-Seq]
GEO Series GSE108383. Homo sapiens. 327 samples. Type: Expression profiling by high throughput sequencing.
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
ClinicalTrials.gov study NCT01841463. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
ClinicalTrials.gov study NCT03088176. IPD Sharing: NO. Countries: 1. Publications: 0.
Association of Hydroxychloroquine, BRAF and MEK Inhibitors in Metastatic Melanoma : a Retrospective Case-control Study.
ClinicalTrials.gov study NCT04760080. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT02906059. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment
ClinicalTrials.gov study NCT05092802. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.